1. Signaling Pathways
  2. Immunology/Inflammation
  3. Interleukin Related

Interleukin Related

IL

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B2176S8
    ATP-13C10,15N5,d14 (dilithium)
    ATP-13C10,15N5,d14 (Adenosine 5'-triphosphate-13C10,15N5,d14) dilithium is the 13C-, 15N- and deuterium labeled ATP dilithium. ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
    ATP-<sup>13</sup>C<sub>10</sub>,<sup>15</sup>N<sub>5</sub>,d<sub>14</sub> (dilithium)
  • HY-P991594
    Anti-IL-13 Antibody (C836)
    Inhibitor
    Anti-IL-13 Antibody (C836) is a neutralizing monoclonal antibody targeting human IL-13. The Fab fragment of Anti-IL-13 Antibody (C836) is a heterodimer composed of heavy chains and light chains, each folded into variable and constant domains. Anti-IL-13 Antibody (C836) can be used for chronic inflammatory diseases, such as asthma.
    Anti-IL-13 Antibody (C836)
  • HY-P990206
    Anti-Mouse Jagged 2 Antibody (HMJ2-1)
    Inhibitor
    Anti-Mouse Jagged 2 Antibody (HMJ2-1) is an anti-mouse Jagged 2 IgG monoclonal antibody. Anti-Mouse Jagged 2 Antibody (HMJ2-1) regulates Treg/Th17 balance through IL-9. Anti-Mouse Jagged 2 Antibody (HMJ2-1) increases Jagged2-Notch signaling through activation of RBP-Jk. Anti-Mouse Jagged 2 Antibody (HMJ2-1) can be used for researches on inflammation conditions and xenotransplantation such as experimental autoimmune encephalomyelitis (EAE).
    Anti-Mouse Jagged 2 Antibody (HMJ2-1)
  • HY-156997
    ABX196
    Agonist
    ABX196 is NKT agonist. ABX196 is an analog of the parental compound -GalCer.
    ABX196
  • HY-116609
    C6 L-threo Ceramide
    Inhibitor
    C6 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. C6 L-threo Ceramide significantly inhibits IL-4 production in T cells. Anti-allergic agents.
    C6 L-threo Ceramide
  • HY-P10994
    Eps8 peptide 327
    Inhibitor
    Eps8 peptide 327 is an HLA-A*2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models.
    Eps8 peptide 327
  • HY-133133
    IIIM-1270
    Inhibitor 98.78%
    IIIM-1270is a NLRP3 inflammasome inhibitor. IIIM-1270 inhibits IL-1β release in mouse macrophages (J774A.1 cells) (IC50 = 3.5 μM) and significantly reduced the protein expression level of mature IL-1β. IIIM-1270 can be used for the study of inflammation.
    IIIM-1270
  • HY-182795
    Colchicine derivative-1
    Activator
    Colchicine derivative-1 is a colchicine derivative. Colchicine derivative-1 exhibits cytotoxicity against various cells. Colchicine derivative-1 arrests cancer cells at the G2/M phase of the cell cycle. Colchicine derivative-1 increases the levels of MMP-2, MMP-8, MMP-9, IL-2, IL-6, IL-17A, IL-22, IL-4, and IL-5 in the blood, inhibits the gene expression of hepatic fibrinogen α, β, γ and TGF-β1, and alleviates hepatic fibrosis symptoms in mice. Colchicine derivative-1 has antifibrotic activity and can be used in studies related to hepatic fibrosis.
    Colchicine derivative-1
  • HY-W014701R
    1,4-Dihydroxy-2-naphthoic acid (Standard)
    Inhibitor
    1,4-Dihydroxy-2-naphthoic acid (Standard) is the analytical standard for 1,4-Dihydroxy-2-naphthoic acid (HY-W014701). 1,4-Dihydroxy-2-naphthoic acid is an orally active aryl hydrocarbon receptor (AhR) agonist and a bifidogenic growth stimulator. 1,4-Dihydroxy-2-naphthoic acid can improve the motor dysfunction in parkinson's disease (PD) model through AhR-dependent and -independent pathways. 1,4-Dihydroxy-2-naphthoic acid exerts anti-inflammatory effects by regulating the gut microbiota (such as promoting the proliferation of Bifidobacterium) and directly regulating the host immune system. 1,4-Dihydroxy-2-naphthoic acid induces apoptosis through G0/G1 cell cycle arrest in human keratinocyte to inhibit psoriasis.
    1,4-Dihydroxy-2-naphthoic acid (Standard)
  • HY-P991282
    KHK2823
    Inhibitor
    KHK2823 is a humanized monoclonal anti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia.
    KHK2823
  • HY-163674
    Mincle agonist 1
    Activator
    Mincle agonist 1 (compound 1c) is a Mincle agonist. Mincle agonist 1 can promote IL-1β expression in BMDM cells. Mincle agonist 1 can be used in immune and inflammation related research.
    Mincle agonist 1
  • HY-178062
    DGKα-IN-10
    Inducer
    DGKα-IN-10 is an orally active and potent DGKα inhibitor with an IC50 of 0.27 nM. DGKα-IN-10 can induce IL-2 release and T cells proliferation. DGKα-IN-10 can be used for the research of cancer, such as colon cancer.
    DGKα-IN-10
  • HY-178053
    AHR agonist 10
    Inhibitor
    AHR agonist 10 is a potent AHR agonist (EC50 = 2.01 nM). AHR agonist 10 can elevate the transcript levels of key AHR downstream pathway target genes, including CYP1A1 and CYP1B1. AHR agonist 10 can downregulate the expression levels of CD36, IL-18 and shows low cytotoxicity (>40 μM) to normal cells. AHR agonist 10 can suppress the expression of CCL5, CCL20, IL-6, IL-8, S100A9, TLR4, TNF-α, and TNFR1, demonstrating that AHR agonist 10 effectively modulate inflammatory responses through AHR dependent signaling pathways. AHR agonist 10 can be used for psoriasis research.
    AHR agonist 10
  • HY-146547
    Anti-inflammatory agent 17
    Inhibitor
    Anti-inflammatory agent 17 is a potent and orally active anti-inflammatory agent. Anti-inflammatory agent 17 inhibits the release of IL-6 and TNF-α in vitro experiments without cytotoxicity. Anti-inflammatory agent 17 exhibits anti-inflammatory activity in vivo. Anti-inflammatory agent 17 has the potential for the research of Acute lung injury (ALI).
    Anti-inflammatory agent 17
  • HY-172594
    HPK1-IN-57
    Activator
    HPK1-IN-57 (Compound 10c) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 value of 0.09 nM. HPK1-IN-57 inhibits the activity of HPK1 kinase, hindering the phosphorylation of the downstream adaptor protein SLP76 (IC50 is 33.74 nM) and effectively stimulating the secretion of the T cell activation marker IL-2 (EC50 is 84.24 nM). HPK1-IN-57 is promising for research of tumor immunotherapy.
    HPK1-IN-57
  • HY-180291
    Anti-inflammatory agent 109
    Inhibitor
    Anti-inflammatory agent 109 (Compound 2m) is an anti-inflammatory agent. Anti-inflammatory agent 109 directly interacts with p65, attenuates aberrant activation of the NF-κB pathway. Anti-inflammatory agent 109 significantly suppresses the release of key pro-inflammatory mediators, including IL-1β, COX-2, and iNOS. Anti-inflammatory agent 109 conferres robust protection against LPS-induced acute liver injury in septic mice.
    Anti-inflammatory agent 109
  • HY-148272
    IL-17A modulator-3
    Modulator 99.37%
    IL-17A modulator-3 (compound 253) is a IL-17A modulator. IL-17A modulator-3 inhibits IL-17A/A with an IC50 value <10 μM. IL-17A modulator-3 can be used for the research of inflammation, cancer and autoimmune disease.
    IL-17A modulator-3
  • HY-N17395
    (6R,7R)-Epoxy-1-oleanen-3-ol
    Inhibitor
    (6R,7R)-Epoxy-1-oleanen-3-ol is a triterpenoid that can be found in Boswellia ovalifoliolata, exhibiting anti-inflammatory activity. (6R,7R)-Epoxy-1-oleanen-3-ol inhibits TNF-α, IL-6, IL-8, and NO production in LPS (HY-D1056)-activated murine neutrophils. (6R,7R)-Epoxy-1-oleanen-3-ol can be used for the research on inflammatory conditions.
    (6R,7R)-Epoxy-1-oleanen-3-ol
  • HY-W753956
    Iminostilbene-d10
    Iminostilbene-d10 is the deuterium labeled Iminostilbene (HY-N7064). Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases.
    Iminostilbene-d<sub>10</sub>
  • HY-B0026R
    Ceftiofur hydrochloride (Standard)
    Inhibitor
    Ceftiofur hydrochloride (Standard) is the analytical standard of Ceftiofur hydrochloride (HY-B0026). This product is intended for research and analytical applications. Ceftiofur hydrochloride is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur hydrochloride exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur hydrochloride also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.
    Ceftiofur hydrochloride (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.